Please ensure Javascript is enabled for purposes of website accessibility

Is There Any Hope for Vaxart Stock?

By Zhiyuan Sun - Feb 5, 2021 at 7:03AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This small-cap biotech just published clinical data for its experimental coronavirus vaccine, and investors are not happy.

A few days ago, Vaxart (VXRT -6.51%) was arguably the best-performing coronavirus vaccine stock of all time. If you had invested $5,000 in the stock last year, that principal would have grown into a stunning $205,000 by Feb. 2. 

But not even 24 hours later, Vaxart stock took a devastating 60% plunge the day it announced interim phase 1 data on its oral-tablet coronavirus vaccine candidate. Just what is behind the wild roller coaster ride? 

Woman taking a pill.

Image source: Getty Images.

Are the results really that bad?

In the interim phase 1 data release, 35 healthy adults who took one dose of Vaxart's oral COVID-19 vaccine developed little to no neutralizing antibody response. That is in stark contrast to currently approved coronavirus vaccines marketed by Pfizer (PFE -1.83%) and Moderna (MRNA -3.21%), which induced neutralizing antibodies in 100% of participants in phase 1. Additionally, only 52% of participants showed twofold or above increases in regular antibody levels.

Even though the tablet produced an immune cell response among 75% of participants, it is unclear why it failed to induce neutralizing antibodies in all individuals. Aside from that, the experimental vaccine was somewhat well tolerated with gastrointestinal issues post-ingestion, the most significant of which was loss of appetite among 2 out of 15 participants in the high-dose cohort. The vaccine candidate is also stable at room temperature and can be delivered to someone's home if it succeeds in later trials.

That probability, however, is very low. The company could theoretically try again with a two-dose or multiple-dose vaccine regimen and hope that it works. But high dosages could also make the vaccine candidate unsafe. 

VXRT Chart

VXRT data by YCharts

Is this the end? 

Vaxart was already far behind in the coronavirus vaccine race before this setback. Right now, the company does not expect its oral-tablet vaccine to finish phase 2/3 investigations until early next year. Meanwhile, mutant strains of the coronavirus are already running rampant across the globe, and experimental coronavirus vaccines are having difficulties combating them. Hence, the barrier to entry is higher now than it was for vaccines designed to combat the original strains of COVID-19.

Vaxart's lackluster results will likely mean the company would have problems finding a development partner to foot the research costs. It has only $133 million cash on hand to offset potentially billions in vaccine development expenses. Therefore, I expect the company, which has a $1 billion market cap, to initiate several sizable stock offerings if it wants to proceed with the project.

Overall, such disappointing data, especially at an early stage, is a big red flag when it comes to biotech investing. The company was already in trouble last year, when it clashed with federal authorities over allegations Vaxart inflating its role in Operation Warp Speed, as well as insider trading.

Unless the company can demonstrate that a two-dose oral tablet can generate significant neutralizing antibodies against COVID-19 or somehow find new, positive data in phase 2, I wouldn't put much faith in its science. Investing in Vaxart at this low point is about as risky as it gets. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Vaxart, Inc. Stock Quote
Vaxart, Inc.
$3.16 (-6.51%) $0.22
Pfizer Inc. Stock Quote
Pfizer Inc.
$50.40 (-1.83%) $0.94
Moderna, Inc. Stock Quote
Moderna, Inc.
$137.71 (-3.21%) $-4.57

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.